In brief
At 65, men in England are offered a one-off ultrasound scan to look for an abdominal aortic aneurysm (AAA), a widening of the main artery through the abdomen.
The evidence that screening reduces deaths from AAA comes from four randomised trials conducted decades ago, when AAA was much more common than it is today. The largest UK trial, MASS, recruited men between 1997 and 1999. When the results of the four trials are combined, screening reduced AAA-related deaths and ruptures. But there has been no equivalent randomised trial in today's much lower-risk population.
In the latest English programme data for 2025/26, about 6–7 AAAs were found for every 1,000 men screened. Most AAAs found at the initial scan are small and are monitored with repeat scans rather than referred straight for an operation. Over time, some grow sufficiently to be referred for possible treatment.
The latest UK model, run in 2024, estimated about 0.9 fewer AAA-related deaths per 1,000 men invited for screening, compared with no invitation to screening. But the model assumed that 0.92% of men screened would have an AAA. The latest English programme found AAA in about 0.64% of men screened, so we do not know exactly how large the modelled benefit would be using today's lower figure.
Screening also has downsides. It can mean years of surveillance, it increases the number of planned AAA operations, and it can detect a real aneurysm that would never have ruptured or shortened that man's life. We cannot know which individual aneurysms those are.
There is also an important distinction between deaths from AAA and deaths from all causes. MASS, the largest individual trial, reported a small reduction in deaths from all causes. When results from the main trials have been combined, some statistical analyses have found a small reduction in deaths from all causes and others have not.
What happens if you go for screening?
The scan is a quick, non-invasive ultrasound of the abdomen.
In England in 2025/26, 352,227 men were offered screening and 82.4% were conclusively tested. The programme found 1,869 AAAs. That works out at about 6.4 AAAs per 1,000 men screened.
If no AAA is found, there is normally no further screening. Small and medium AAAs are monitored with repeat scans. Large AAAs, or aneurysms that grow rapidly, are referred to a vascular service to consider treatment.
Most aneurysms found at the initial scan are small.
What benefit did the original trials find?
The strongest evidence that screening reduces deaths from AAA comes from randomised trials conducted decades ago.
The largest was the UK Multicentre Aneurysm Screening Study (MASS), which recruited 67,770 men aged 65–74 between 1997 and 1999. After about 13 years there had been 224 AAA-related deaths among men invited for screening, compared with 381 among men who were not invited.
That is about 46 fewer AAA-related deaths per 10,000 men invited over 13 years.
Other randomised trials conducted around the same period also found fewer AAA-related deaths overall when their results were combined with MASS in a later evidence review.
How large is the benefit today?
MASS began in the late 1990s. Among men aged 65–74 who attended screening, 4.9% had an AAA detected. The English programme now routinely screens men at 65, so the figures are not directly age-comparable. However, AAA prevalence — the proportion of men screened who have an AAA — has also fallen substantially within the modern programme itself. The latest English figure is about 0.64% among men screened.
There has not been an equivalent modern randomised trial at today's much lower prevalence.
Instead, the latest UK assessment used a computer model. The model, run in 2024, compared 300,000 men invited to screening in the year of their 65th birthday with 300,000 men not invited. It estimated 267 fewer AAA-related deaths in the invited group. That is about 0.9 fewer AAA-related deaths per 1,000 men invited, or roughly one fewer for every 1,100 invited.
But there is an important qualification. The model used an AAA prevalence of 0.92%, based on 2019/20 data. The latest English programme is now finding AAA in about 0.64% of men screened.
If the modelled benefit fell in the same proportion as the percentage of men found to have an AAA — from 0.92% to 0.64% — the figure would fall from about 0.9 to 0.6 fewer AAA-related deaths per 1,000 men invited.
This is an illustrative calculation by The Assertion, not a result produced by the model. The model includes other factors as well as prevalence, so 0.6 per 1,000 should not be treated as an estimate of what the model would produce if it were rerun using today's prevalence.
What we can say is that the model used a higher prevalence than is now observed in England. What we cannot establish from this simple calculation is exactly how much that changes the modelled benefit.
What are the downsides of going for AAA screening?
The ultrasound itself is simple, but the consequences of screening do not necessarily end with the scan.
Finding a small or medium AAA can mean years of surveillance. Diagnosis can also cause anxiety for some men, although research suggests that at least some of the effect on mental quality of life is temporary.
Screening also increases planned surgery. In MASS there were 600 elective AAA operations among about 33,900 men invited to screening, compared with 277 among about 33,900 controls. That is approximately 177 versus 82 elective operations per 10,000 men. Emergency operations fell from about 49 to 24 per 10,000, but total AAA operations increased from about 131 to 201 per 10,000.
Some of those additional planned operations prevented later rupture. That is part of how screening works. But screening can also find a real aneurysm that would never have ruptured or shortened that man's life. This is called overdiagnosis.
The exact amount of overdiagnosis is uncertain. Surgery also carries its own risk of complications and death.
Does AAA screening help you live longer?
That is a different question from whether screening reduces deaths from AAA.
MASS, the largest individual trial, reported that the rate of death from all causes was about 3% lower among men invited to screening after about 13 years.
When the main trials have been combined, the result depends slightly on the statistical analysis used. A major 2019 evidence review did not find a reduction in deaths from all causes that met the usual statistical threshold, while other analyses combining the trials have found a small reduction that did.
The latest UK model also estimated that screening would result in men living slightly longer on average. But that was a modelled projection, not a difference demonstrated in a modern randomised trial.
What does the evidence tell us overall?
AAA screening can detect aneurysms before rupture, and randomised trials conducted decades ago found that screening reduced deaths caused by AAA.
But we do not know exactly how large that benefit would be today. AAA is now much less common in 65-year-old men than it was when the main trials were conducted, and today's absolute benefit has to be estimated using modelling rather than a new randomised trial. The latest UK model itself used a higher proportion of men with AAA than is now observed in England.
There are also trade-offs. Screening finds some aneurysms that require surveillance, creates additional planned operations and can identify aneurysms that would never otherwise have caused harm.
And the average figures do not apply equally to every man. Smoking history, age and other risk factors affect the chance of having an AAA.